Immunogenicity of the <i>Xcl1</i>-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19

Immunogenicity of the <i>Xcl1</i>-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19

SARS-CoV-2 spike (S) variants that may evade antibody-mediated immunity are emerging. Evidence shows that vaccines with a stronger immune response are still effective against mutant strains. Here, we report a targeted type 1 conventional dendritic (cDC1) cell strategy for improved COVID-19 vaccine d...

Full description

Bibliographic Details
Main Authors: Hailong Qi, Zhongjie Sun, Yanling Yao, Ligong Chen, Xuncheng Su
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Vaccines
Subjects:
SARS-CoV-2
Xcl1
DNA vaccine
Online Access:https://www.mdpi.com/2076-393X/10/3/407

Similar Items

Similar Items